DT Investment Partners LLC Sells 4,647 Shares of Johnson & Johnson (NYSE:JNJ)

DT Investment Partners LLC cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 7.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 59,401 shares of the company's stock after selling 4,647 shares during the period. Johnson & Johnson accounts for 0.7% of DT Investment Partners LLC's investment portfolio, making the stock its 27th biggest position. DT Investment Partners LLC's holdings in Johnson & Johnson were worth $8,591,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of JNJ. International Assets Investment Management LLC increased its holdings in shares of Johnson & Johnson by 20,130.0% in the third quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company's stock worth $559,832,000 after purchasing an additional 3,437,397 shares during the period. Janus Henderson Group PLC grew its position in Johnson & Johnson by 228.1% during the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company's stock worth $549,223,000 after buying an additional 2,356,359 shares in the last quarter. Franklin Resources Inc. increased its stake in Johnson & Johnson by 11.4% in the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock worth $2,721,355,000 after acquiring an additional 1,729,281 shares during the last quarter. Holocene Advisors LP purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $225,040,000. Finally, FMR LLC boosted its position in shares of Johnson & Johnson by 7.4% during the 3rd quarter. FMR LLC now owns 18,316,920 shares of the company's stock valued at $2,968,440,000 after acquiring an additional 1,265,748 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price objective on the stock. Raymond James lowered their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Citigroup cut their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Royal Bank of Canada restated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday. Finally, StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $170.67.

Johnson & Johnson Trading Up 1.7 %

Shares of Johnson & Johnson stock traded up $2.67 on Friday, hitting $162.35. The stock had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The stock's 50-day simple moving average is $148.93 and its two-hundred day simple moving average is $155.90. The stock has a market cap of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.53 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the firm earned $2.29 EPS. The company's revenue was up 5.3% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is currently 74.59%.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company's stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.